Cell therapy and targeted agents are transforming blood cancer outcomes, but infrastructure, funding, and workforce gaps are ...

Adaptive trials like I-SPY have lifted breast cancer complete response rates to 50%–60%, but better early end points are needed for wider use.

Quantification across 204 countries attributed CKD DALYs to seven dietary risks and four etiologic categories (T2D, ...

After adjustment for demographic and clinical risk factors, discrimination in each domain was associated with higher heart failure risk, and risk increased with cumulative exposure. Women who reported ...

An expert discusses gaps in pediatric alopecia areata evidence, missed trial outcomes, and what managed care should change ...

Population Health, Equity & Outcomes is a quarterly publication dedicated to providing a platform for the exchange of research, policy analysis, and insights that aim to improve health outcomes and ...

Arshad Khanani, MD, weighs Wnt- and Tie2-targeting agents against gene therapy and makes the case for payers to look past price to long-term value.

Katherine Wilemon, Family Heart Foundation, described the biggest unmet need when it comes to public awareness of Lp(a) and ...

The cereblon E3 ligase modulator, or CELMoD, also received a breakthrough therapy designation from the FDA. The FDA has granted an accelerated approval to the regimen ...

Disease-modifying antirheumatic drug (DMARD) and tumor necrosis factor (TNF) cycling is a real and well-documented problem in ...

The Women’s Health Initiative, launched in 1991 across 40 centers with >161,000 participants, materially influenced practice ...

The FDA approved Moderna’s Biologics License Application (BLA) for its mRNA-based flu vaccine, mRNA-1010 (mFlusiva; Moderna), ...